MelissaGarigBrammerMD

PubMed

• 7 citations
  Estimated Life-Years Saved in Women with HER2-Positive Metastatic Breast Cancer Receiving First-Line Trastuzumab and Pertuzumab in the United States
  Mark D. Danese, Anthony Masaquel, Eduardo Santos, Melissa Brammer, Abraham Lee, Deepa Lalla> ;Value in Health. 2015 Sep 1
• 14 citations
  The Lifetime Economic Burden of Inaccurate HER2 Testing: Estimating the Costs of False-Positive and False-Negative HER2 Test Results in US Patients with Early-Stage Br...
  Louis P. Garrison, Joseph B. Babigumira, Anthony Masaquel, Bruce Wang, Deepa Lalla, Melissa Brammer> ;Value in Health. 2015 Jun 1
• 3 citations
  Symptom burden and quality of life among women with HER2(+) metastatic breast cancer.
  Musa Mayer, Kathleen Lang, Sara A. Hurvitz, Deepa Lalla, Victoria Federico, Melissa Brammer, Joseph Menzin, Debu Tripathy> ;The Breast Journal. 2015 Mar 1
• 47 citations
  Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer.
  Peter A. Kaufman, Kenneth J. Bloom, Howard A. Burris, Julie R. Gralow, Musa Mayer, Mark D. Pegram, Hope S. Rugo, Sandra M. Swain, Denise A. Yardley, Miu Chau, Deepa La...> ;Cancer. 2014 Sep 1
• 50 citations
  Investigation of Adverse-Event-Related Costs for Patients With Metastatic Breast Cancer in a Real-World Setting
  Sara A. Hurvitz, Annie Guerin, Melissa Brammer, Ellie Guardino, Zheng-Yi Zhou, Dominick Latremouille Viau, Eric Q. Wu, Deepa Lalla> ;The Oncologist. 2014 Sep 1
• 23 citations
  Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens
  Ryan N. Hansen, Scott D. Ramsey, Deepa Lalla, Anthony Masaquel, Tripthi Kamath, Melissa Brammer, Sara A. Hurvitz, Sean D. Sullivan> ;Springerplus. 2014 May 21
• 4 citations
  Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis
  Annie Guerin, Deepa Lalla, Geneviève Gauthier, Amy Styles, Eric Q. Wu, Anthony Masaquel, Melissa Brammer> ;Springerplus. 2014 May 8
• 27 citations
  Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status
  Louis P. Garrison, Deepa Lalla, Melissa Brammer, Joseph B. Babigumira, Bruce C. M. Wang, Edith A. Perez> ;Cancer. 2013 Sep 1
• 10 citations
  Effect of Central Nervous System Metastases on Treatment Discontinuation and Survival in Older Women Receiving Trastuzumab for Metastatic Breast Cancer
  Mark D. Danese, Karla Lindquist, Justin F. Doan, Deepa Lalla, Melissa Brammer, Robert I. Griffiths> ;Journal of Cancer Epidemiology. 2012 Apr 9
• 18 citations
  Infused therapy and survival in older patients diagnosed with metastatic breast cancer who received trastuzumab
  Robert I. Griffiths, Deepa Lalla, Robert J. Herbert, Justin F. Doan, Melissa Brammer, Mark D. Danese> ;Cancer Investigation. 2011 Oct 19
• 270 citations
  Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER
  Adam Brufsky, Musa Mayer, Hope S. Rugo, Peter A. Kaufman, Elizabeth Tan-Chiu, Debasish Tripathy, Iulia Cristina Tudor, L. Wang, Melissa Brammer, Mona Shing, Marianne U...> ;Clinical Cancer Research. 2011 Jul 15
• Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.
  Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M> ;J. Clin. Oncol.. 2011-05-20
• Assessment of burden of illness in women with HER2+ metastatic breast cancer: Findings from a community web-based survey.
  Mayer M, Doan JF, Lang K, Hurvitz SA, Lalla D, Woodward RM, Brammer M, Menzin J, Tripathy D> ;J. Clin. Oncol.. 2011-05-20
• Assessing the potential cost-effectiveness of retesting IHC0, IHC1-positive, or FISH-negative early-stage breast cancer patients for HER2 status.
  Garrison LP, Lalla D, Brammer MG, Wang B, Babigumira J, Perez EA> ;J. Clin. Oncol.. 2011-05-20
• Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.
  Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA> ;J. Clin. Oncol.. 2011-05-20
• 10 citations
  Estimating Recurrences Prevented From Using Trastuzumab in HER-2/neu-Positive Adjuvant Breast Cancer in the United States
  Mark D. Danese, Deepa Lalla, Melissa Brammer, Quan Doan, Kevin B. Knopf> ;Cancer. 2010 Dec 15
• registHER: Treatment outcomes in patients with HER2-positive (HER2+), hormone receptor-positive (HR+) metastatic breast cancer (MBC).
  Tripathy D, Kaufman P, Brufsky A, Mayer M, Yood M, Wang L, Brammer M, Yardley D, Tan-Chiu E, Rugo H> ;J. Clin. Oncol.. 2009-05-20
• 10 citations
  Adult T-cell leukemia-lymphoma. Unusual features of two patients from a low-incidence area.
  Judith J. Temple, Melissa G. Brammer, W. Abe Andes, Steve Covington, Setular Rangan> ;Cancer. 1986 Aug 1
• Join now to see all